Predicting Time to Virologic Failure in HIV-1 Patients on New Treatment
Author Information
Author(s): Mattia CF Prosperi, Simona Di Giambenedetto, Iuri Fanti, Genny Meini, Bianca Bruzzone, Annapaola Callegaro, Giovanni Penco, Patrizia Bagnarelli, Valeria Micheli, Elisabetta Paolini, Antonio Di Biagio, Valeria Ghisetti, Massimo Di Pietro, Maurizio Zazzi, Andea De Luca
Primary Institution: Catholic University of the Sacred Heart, Rome, Italy
Hypothesis
Can genotypic susceptibility scores (GSSs) predict the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen?
Conclusion
The study found that GSSs and other factors can help predict the time to virologic failure in HIV-1 patients on new treatments.
Supporting Evidence
- 2337 cART regimens were analyzed from 2182 patients.
- 1067 virologic failures were observed over 2820 person-years.
- RSF showed better predictive performance than Cox regression.
Takeaway
This study looks at how long HIV patients can stay healthy on new treatments and finds ways to predict when they might get sick again.
Methodology
The study analyzed data from the Italian ARCA cohort, using Cox regression and random survival forests to assess the time to virologic failure.
Potential Biases
Potential bias due to exclusion of early treatment switches and reliance on a specific viral load threshold for defining virologic failure.
Limitations
The study only included patients on treatment for at least 90 days, which may introduce selection bias.
Participant Demographics
The cohort included 2182 patients, with 34% being treatment-naïve and a median age of 40 years.
Statistical Information
P-Value
< 0.0001
Confidence Interval
95% CI for median time to virologic failure was 533-784 days.
Statistical Significance
p < 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website